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Summary
Background Urine tests for mycobacterial lipoarabinomannan might be useful for point-of-care diagnosis of 
tuberculosis in adults with advanced HIV infection, but have not been assessed in children. We assessed the accuracy 
of urine lipoarabinomannan testing for the diagnosis of pulmonary tuberculosis in HIV-positive and HIV-negative 
children.
Methods We prospectively recruited children (aged ≤15 years) who presented with suspected tuberculosis at a primary 
health-care clinic and paediatric referral hospital in South Africa, between March 1, 2009, and April 30, 2012. We assessed 
the diagnostic accuracy of urine lipoarabinomannan testing with lateral ﬂ ow assay and ELISA, with mycobacterial culture 
of two induced sputum samples as the reference standard. Positive cultures were identiﬁ ed by acid-fast staining and 
tested to conﬁ rm Mycobacterium tuberculosis and establish susceptibility to rifampicin and isoniazid.
Findings 535 children (median age 42·5 months, IQR 19·1–66·3) had urine and two induced specimens available for 
testing. 89 (17%) had culture-conﬁ rmed tuberculosis and 106 (20%) had HIV. The lateral ﬂ ow lipoarabinomannan test 
showed poor accuracy against the reference standard, with sensitivity of 48·3% (95% CI 37·6–59·2), speciﬁ city of 
60·8% (56·1–65·3), and an area under the receiver operating characteristic curve of 0·53 (0·46–0·60) for children 
without HIV and 0·64 (0·51–0·76) for children with HIV. ELISA had poor sensitivity in children without HIV 
(sensitivity 3·0%, 95% CI 0·4–10·5) and children with HIV (0%, 0·0–14·3); overall speciﬁ city was 95·7% (93·4–97·4).
Interpretation Urine lipoarabinomannan tests have insuﬃ  cient sensitivity and speciﬁ city to diagnose HIV-positive 
and HIV-negative children with tuberculosis and should not be used in this patient population.
Funding US National Institutes of Health, the National Health Laboratory Services Research Trust, the Medical 
Research Council of South Africa, and the Wellcome Trust.
Copyright © Nicol et al. Open Access article distributed under the terms of CC BY.
Introduction
Microbiological conﬁ rmation of pulmonary tuberculosis 
in children is diﬃ  cult. Collection of a sample from the 
lower respiratory tract is challenging because young 
children rarely spontaneously produce sputum. Sputum 
induction or gastric lavage are useful methods for 
obtaining respiratory samples,1 but require trained staﬀ  
and basic equipment. Even when appropriate samples 
can be obtained, smear microscopy is rarely positive in 
children and mycobacterial culture is often required.2 
The main drawback of culture is that treatment decisions 
often need to be made before results are available 
because the clinical course of tuberculosis can be rapid 
in children younger than 5 years. Moreover, culture 
requires advanced infrastructure and trained staﬀ  and is 
therefore seldom available in countries with the greatest 
burden of disease. We recently reported on the accuracy 
of Xpert MTB/RIF testing of induced sputum3 and naso-
pharyngeal aspirate4 specimens, which holds promise as 
a rapid and feasible alternative to culture in low-resource 
settings.
A urine test would simplify specimen collection for 
children with suspected pulmonary tuberculosis. Studies 
of urine tests5–9 for tuberculosis in adults with suspected 
tuberculosis have shown mixed results. Two approaches 
have been assessed. First, detection of small fragments of 
Mycobacterium tuberculosis DNA in urine5 showed initial 
promise, but early ﬁ ndings have not been conﬁ rmed. 
Second, urine tests for mycobacterial lipoarabinomannan, 
in both ELISA and lateral ﬂ ow assay format, have been 
assessed in adults with suspected tuberculosis.6–8 The 
tests are sensitive in adults with advanced HIV disease 
but not in HIV-negative adults and HIV-positive adults 
with CD4 counts higher than 100 cells per L.9 The lateral 
ﬂ ow assay version of the lipoarabinomannan test might 
be the ﬁ rst point-of-care test for tuberculosis with 
diagnostic utility. In a recent Comment in The Lancet 
Global Health,10 Van Rie outlined the need to assess the 
lipoarabinomannan test in children.
Young children with pulmonary tuberculosis develop 
disseminated disease more frequently than do adults; 
therefore, urine lipoarabinomannan testing might be 
useful for the diagnosis of pulmonary tuberculosis in 
children, including those without HIV. HIV-positive 
children are especially at risk for disseminated 
tuberculosis. Therefore, we prospectively assessed the 
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accuracy of urine lipoarabinomannan testing in ELISA 
and lateral ﬂ ow assay formats in HIV-positive and HIV-
negative children presenting with suspected pulmonary 
tuberculosis to a primary health-care clinic or to a referral 
hospital in Cape Town, South Africa.
Methods
Study design and participants
We enrolled children aged 15 years or younger who 
presented with suspected pulmonary tuberculosis to Red 
Cross War Memorial Children’s Hospital (a tertiary referral 
hospital) or Nolungile Clinic (a primary health-care 
facility), between March 1, 2009, and April 30, 2012. 
Suspected pulmonary tuberculosis was deﬁ ned on the 
basis of cough of any duration and one of the following: 
household contact with an infectious tuberculosis source 
case within the preceding 3 months, loss of weight or 
failure to gain weight in the preceding 3 months 
(established by either documented weight loss on growth 
chart or parental report), a positive tuberculin skin test to 
puriﬁ ed protein derivative (2TU, PPD RT23, Staten Serum 
Institute, Denmark, Copenhagen), or a chest radiograph 
suggesting pulmonary tuberculosis (including airway 
compression or lymphadenopathy, diﬀ use miliary pattern, 
pleural eﬀ usion, or cavitary disease). A positive tuberculin 
skin test was deﬁ ned as 5 mm or more of transverse 
induration in children with HIV or 10 mm or more in 
children without HIV. Children were excluded if they had 
received more than 72 h of treatment or prophylaxis for 
tuberculosis, if they were not resident in Cape Town and 
could not be followed up, if informed consent was not 
obtained, or if two induced sputum and one urine 
specimen could not be obtained.
Written, informed consent for enrolment in the study 
was obtained from a parent or legal guardian. The 
Research Ethics Committee of the Faculty of Health 
Sciences, University of Cape Town, and the Provincial 
Government of the Western Cape approved the study. 
Tuberculosis treatment was started at the discretion of 
the treating doctor on the basis of clinical, radiological, 
and microbiological information. Follow-up visits were 
done at 1, 3, and 6 months for children on tuberculosis 
treatment and at 1 and 3 months for those not treated. To 
assess response to treatment at follow-up, we recorded 
symptoms, signs, and weight, and repeated chest 
radiograph at completion of tuberculosis treatment.
Procedures
A history and physical examination were done in all 
children by a study doctor. Routine clinical investigations 
included chest radiography, tuberculin skin test, and 
HIV testing in children with unknown HIV status (HIV 
rapid test, followed by a conﬁ rmatory PCR for children 
aged <18 months or HIV ELISA in children aged 
>18 months). CD4 count and HIV viral load were tested, 
and HIV-positive children were categorised with WHO 
clinical and immunological classiﬁ cation.11
Two consecutive induced sputum specimens were 
obtained in children for microbiological conﬁ rmation of 
tuberculosis as previously described3 and submitted for 
smear and liquid culture. Induced sputum specimens 
were transported within 2 h of collection to an accredited, 
centralised laboratory at Groote Schuur Hospital, Cape 
Town,  and processed individually with standardised 
protocols by trained technologists. For both specimens, 
after decontamination with N-acetyl-L-cysteine and 
sodium hydroxide (1·0% ﬁ nal concentration), centrifuged 
deposits were resuspended in 1·5 mL phosphate buﬀ er. A 
drop of induced sputum sediment was used for ﬂ uorescent 
acid-fast smear microscopy. Automated liquid culture 
testing (BACTEC MGIT, Becton Dickinson, Cockeysville, 
MD, USA) was done with 0·5 mL resuspended pellet. 
Cultures were incubated for up to 6 weeks. Positive 
cultures were identiﬁ ed by acid-fast staining followed by 
MTBDRplus testing (Hain Lifescience, Nehren, Germany) 
to conﬁ rm M tuberculosis and to establish susceptibility to 
rifampicin and isoniazid.
Urine was collected from children with specimen bags, 
unless children were old enough to voluntarily produce a 
specimen on demand. All urine specimens were frozen 
within 2 h of collection at –80°C, and were tested within 
24 months of storage. For the lateral ﬂ ow assay, 60 μL of 
thawed urine was applied to the test strip, incubated at 
room temperature for 25 min, visually inspected, and the 
intensity of any visualised test band was graded by 
comparison of band intensity with the manufacturer-
supplied reference card by one research laboratory 
technician trained in this technique. Test band intensity 
was graded as zero if no band was visualised, and 
grade 1–5 for visualised bands, according to the band on 
the reference card that most closely matched the test 
band. Clearview tuberculosis ELISA (Alere, Waltham, 
MA, USA) was done according to the manufacturer’s Figure 1: Study proﬁ le
3541 children screened
2488 children excluded
 2312 not eligible
 172 discharged
 4 withdrew
1053 children enrolled
518 excluded
 356 no urine specimen
 162 without 2 valid induced 
  sputum cultures
535 included in analysis
 89 definite tuberculosis
 250 possible tuberculosis
 196 not tuberculosis
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recommendations. Staﬀ  who did and recorded urine 
tests were masked to culture results and to the presenting 
clinical features. Results of lipoarabinomannan testing 
were not communicated to the treating doctor.
Tuberculosis diagnostic categorisation was based on 
clinical and microbiological investigations: deﬁ nite 
tuberculosis (any induced sputum culture positive for 
M tuberculosis), not tuberculosis (culture negative, no 
tuberculosis treatment given, and documented resolution 
of symptoms and signs at 3 month follow-up visit), or 
possible tuberculosis (all other children, including 
children given tuberculosis treatment without culture 
conﬁ rmation and children with negative culture for 
M tuberculosis not given tuberculosis treatment and who 
did not have documented resolution of symptoms and 
signs at follow-up either because of loss to follow-up or 
persistent symptoms or signs at follow-up).
Statistical analysis
For the primary analysis of the accuracy of lateral ﬂ ow 
assay and ELISA, we used mycobacterial culture (ie, 
deﬁ nite tuberculosis) as the reference standard. For a 
secondary analysis, we used a composite reference 
standard including a clinical decision to start tuberculosis 
treatment plus mycobacterial culture. We established 
sensitivity, speciﬁ city, and predictive values of the assays 
with 95% CIs. For lateral ﬂ ow assay we derived receiver 
operating characteristic (ROC) curves by use of the 
diﬀ erent intensities of bands. Data were entered into 
Microsoft Access and analysed with STATA (version 10) 
and EpiInfo (version 6) for calculation of nutritional 
indices. We used simple descriptive statistics to 
characterise the study population. Normally distributed 
continuous data were summarised by mean and 95% 
CIs, and non-normally distributed continuous data by 
median and IQR. Categorical data were summarised as 
proportions with 95% CI. Statistical tests used were 
χ² test of association, χ² test for trend, Kruskal-Wallis, 
two-group test of equal proportions, and the ROC 
compare test.
We used multinomial regression to explore the possible 
eﬀ ect of antiretroviral therapy (ART) and immune category 
on lateral ﬂ ow assay (≥1 intensity) in children with HIV, 
and the possible eﬀ ect of HIV status, age, tuberculin skin 
test result, and nutritional status on lateral ﬂ ow assay 
(≥1 intensity) across the categories of tuberculosis 
diagnosis, with not tuberculosis as the reference category. 
Statistical tests were two-sided at α of 0·05.
Overall
(n=535)
Deﬁ nite 
tuberculosis 
(n=89)
Possible 
tuberculosis 
(n=250)
Not
tuberculosis 
(n=196)
p value* p value†
Median age (years; IQR) 42·5 (19·1–66·3) 52·7 (26·8–93·3) 37·2 (17·8– 64·3) 42·3 (18·0–65·2) 0·007 0·005
Boys 302 (57%) 61 (69%) 140 (56%) 101 (52%) 0·03 0·007
Cough (any duration) 426 (81%) 76 (85%) 192 (77%) 158 (81%) 0·16 0·33
Fever‡ 270 (51%) 45 (51%) 126 (50%) 99 (51%) 1·00 1·00
Weight loss§ 334 (62%) 64 (72%) 160 (64%) 110 (56%) 0·03 0·01
HIV positive 106 (20%) 23 (26%) 49 (20%) 34 (17%) 0·25 0·10
Started on ART 35 (33%) 9 (39%) 11 (23%) 3 (44%) 0·16 0·71
WHO HIV clinical classiﬁ cation 106 (20%) 23 (26%) 49 (20%) 34 (17%) ·· 0·01
Stage 1 13 (12%) 0 (0%) 3 (6·1) 10 (29%) 0·001 ··
Stage 2 19 (18%) 1 (4%) 12 (24·5) 6 (18%) 0·12 ··
Stage 3 58 (55%) 15 (65%) 27 (55·1) 16 (47%) 0·40 ··
Stage 4 16 (15%) 7 (30%) 7 (14·3) 2 (6%) 0·05 ··
WHO classiﬁ cation of HIV–associated 
immunodeﬁ ciency
99 (19%) 22 (25%) 48 (19%) 29 (15%) ·· 0·78
None or not signiﬁ cant 32 (32%) 8 (36%) 10 (21%) 14 (48%) 0·04 ··
Mild 14 (14%) 2 (9%) 10 (21%) 2 (7%) 0·21 ··
Advanced 12 (12%) 3 (14%) 7 (15%) 2 (7%) 0·67 ··
Severe 41 (41%) 9 (41%) 21 (44%) 11 (38%) 0·90 ··
HAZ (IQR) –1·0 (–2·1 to –0·1) –1·1 (–2·2 to –0·2) –1·1 (–2·1 to –0·1) –0·9 (–1·9 to –0·1) 0·53 0·35
WAZ (IQR) –0·9 (–1·9 to 0·1) –1·1 –2·4 to –0·1) –1·0 (–2·0 to –0·4) –0·7 (–1·7 to 0·2) 0·07 0·61
WHZ (IQR) –0·1 (–1·1 to 0·8) –0·4 (–1·3 to 0·5) –0·1 (–1·2 to 0·8) 0·0 (–0·8 to 0·9) 0·26 0·12
Underweight for age (WAZ ≤2) 121 (23%) 27 (30%) 56 (23%) 38 (20%) 0·16 0·04
TST 283 (58%) 65 (77%) 145 (63%) 73 (42%) 0·25 0·001
Data are n (%) unless otherwise stated. ART=antiretroviral therapy. HAZ=height-for-age Z score. WAZ=weight-for-age Z score. WHZ=weight-for-height Z score. 
TST=tuberculin skin test. *Comparison between children with deﬁ nite tuberculosis, possible tuberculosis, and not tuberculosis. †Comparison between children with deﬁ nite 
tuberculosis and children with not tuberculosis. ‡Deﬁ ned as core temperature >38·5oC. §Any documented weight loss on growth chart or by parental report.
 Table 1: Baseline characteristics of participants
For EpiInfo see http://wwwn.
cdc.gov/epiinfo/
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Role of funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation or 
writing of the report. The corresponding author had full 
access to all the data in the study and responsibility for 
the decision to submit for publication.
Results
We enrolled 1053 children, of whom 518 were excluded, 
mostly because no urine specimen was available (ﬁ gure 1). 
We included 535 children with one urine and two induced 
sputum specimens in the analysis (201 [38%] from 
Nolungile Clinic and 334 [62%] from Red Cross War 
Memorial Children’s Hospital), of whom 89 (17%) had 
deﬁ nite tuberculosis, 250 (47%) had possible tuberculosis, 
and 196 (37%) did not have tuberculosis (ﬁ gure 1). Of the 
518 excluded children, the proportions with deﬁ nite 
tuberculosis (63 [13%]), possible tuberculosis (281 [54%]), 
and not tuberculosis (173 [33%]) were similar to those 
included in the analysis.
Table 1 shows baseline characteristics of participants. 
Cough, fever, and weight loss were the most common 
presenting complaints (table 1). A clinical decision to 
start tuberculosis treatment was made in 294 of 535 
(55%) children, of whom 87 of 89 were in the deﬁ nite 
tuberculosis group and 207 of 250 were in the possible 
tuberculosis group. Children in the deﬁ nite tuberculosis 
group not started on tuberculosis treatment were lost to 
follow-up after enrolment. 489 children had a Mantoux 
result (283 [58%] had a positive result). No child at 
Nolungile Clinic needed hospital admission and we 
recorded no in-hospital deaths in children enrolled at 
Red Cross War Memorial Children’s Hospital. Median 
duration of hospital stay for children at Red Cross War 
Memorial Children’s Hospital was 3 days (IQR 2–7). 
HIV infection was more common in children who 
presented to the hospital (84 of 334 [25%]) than in those 
at the primary care clinic (22 of 201 [11%]; odds ratio 
[OR] 2·73, 95% CI 1·64–4·53). 35 of 106 (33%) children 
with HIV were taking ART at enrolment. Of these 
children, 20 (57%) were started on tuberculosis 
treatment.
Most children (317 [59%]) tested negative, or had a 
band intensity of 1 or stronger (111 [21%]) on lateral ﬂ ow 
assay, with 52 (10%) having a band intensity of 2 or 
stronger, and the remaining 55 (10%) a band intensity 
of 3 or stronger. For the primary analysis, we assessed 
the accuracy of the lipoarabinomannan lateral ﬂ ow assay 
with culture-conﬁ rmed tuberculosis as the reference 
standard. With 1 or greater band intensity as the cutoﬀ , 
sensitivity and speciﬁ city were low in all participants 
(table 2). Accuracy was very poor for all band intensities, 
with an area under the ROC curve of 0·56 
(95% CI 0·50–0·62; appendix).
The proportion of positive tests was similar in children 
with deﬁ nite tuberculosis, possible tuberculosis, and 
not tuberculosis irrespective of band intensity cutoﬀ 
(table 3). When accuracy was stratiﬁ ed by HIV status 
(ﬁ gure 2), we recorded no signiﬁ cant diﬀ erence between 
the area under the ROC curve for HIV-positive (0·64, 
95% CI 0·51–0·76) and HIV-negative children (0·53, 
0·46–0·60; p=0·14). When HIV-positive children were 
stratiﬁ ed by WHO immunological status, sensitivity 
was similar for children categorised as having no or 
insigniﬁ cant immune suppression and those with 
severe immunosuppression; speciﬁ city remained poor, 
irrespective of amount of immune suppression (table 2).
Children with apparent false-positive lateral ﬂ ow assay 
results (children in the not tuberculosis group with 
lateral ﬂ ow assay ≥1 band intensity) were less likely than 
were other children to have a positive Mantoux test 
(23 of 68 [34%] vs 260 of 421 [62%]; relative risk [RR] 0·39, 
95% CI 0·16–0·91), but were of a similar age to other 
children (median 35·4 months [95% CI 16·7–71·1] vs 
44·3 months [21·1–66·3]).
Multinomial regression analysis showed that children 
older than 12 months with a positive Mantoux test had an 
increased risk of deﬁ nite tuberculosis rather than not 
tuberculosis (RR 2·58, 95% CI 1·05–6·31 for age and 
4·89, 2·69–8·87 for Mantoux status). After adjustment 
for the eﬀ ect of age, HIV status, nutritional status, and 
Mantoux status, children with a positive lateral ﬂ ow assay 
test were more likely than were children with a negative 
Sensitivity test positive/
total positive (%, 95% CI)
Speciﬁ city test negative/
total negative (%, 95% CI)
LFA band intensity ≥1
All children (n=535) 43/89 (48·3%, 37·6–59·2) 271/446 (60·8%, 56·1–65·3)
HIV positive (n=106)
All HIV positive 15/23 (65·2%, 42·7–83·6) 47/83 (56·6%, 45·3–67·5)
None or not signiﬁ cant 6/8 (75·0%, 34·9 – 96·8) 13/24 (54·2%, 32·8–74·4)
Mild 0/2 (0·0%, 0·0–65·8) 7/12 (58·3%, 27·7–84·8)
Advanced 1/3 (33·3%, 0·8–90·6) 5/9 (55·6%, 21·2–86·3)
Severe 7/9 (77·8%, 40·0–97·2) 17/32 (53·1%, 34·7–70·9)
HIV negative (n=429) 28/66 (42·4%, 30·3–55·2) 224/363 (61·7%, 56·5–66·7)
LFA band intensity ≥2
All children (n=535) 26/89 (29·2%, 20·1–39·8) 365/446 (81·8%, 77·9–85·3)
HIV positive (n=106)
All HIV positive 10/23 (43·5%, 23·2–65·5) 66/83 (79·5%, 69·2–87·6)
None or not signiﬁ cant 5/8 (62·5%, 24·5–91·5) 20/24 (83·3%, 62·6–95·3)
Mild 0/2 (0·0%, 0·0–65·7) 9/12 (75·0%, 42·8–4·5)
Advanced 1/3 (33·3%, 0·8–90·6) 5/9 (55·6%, 21·2–86·3)
Severe 4/9 (44·4%, 13·7–78·8) 27/32 (84·4%, 67·2–94·7)
HIV negative (n=429) 16/66 (24·2%, 14·5–36·4) 299/363 (82·3%, 78·1–86·1)
ELISA
All children (n=535) 2/89 (2·3%, 0·3–7·9) 427/446 (95·7%, 93·4–97·4
HIV positive (n=106) 0/23 (0·0%, 0·0–14·3) 79/83 (95·2%, 88·1– 98·7)
HIV negative (n=429) 2/66 (3·0%, 0·4–10·5) 348/363 (95·9%, 93·3–97·7)
LFA=lateral ﬂ ow assay. ART=antiretroviral therapy.
Table 2: Sensitivity and speciﬁ city of lipoarabinomannan lateral ﬂ ow assay and ELISA with culture-
conﬁ rmed tuberculosis as the reference standard, stratiﬁ ed by HIV status and WHO HIV immunological 
staging
See Online for appendix
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test result to have deﬁ nite tuberculosis rather than not 
tuberculosis (RR 1·81, 95% CI 1·04–3·14). This eﬀ ect 
was not noted when we compared children with possible 
tuberculosis with those without tuberculosis (1·11, 
0·73–1·69).
In children with HIV, multinomial regression did not 
show any signiﬁ cant eﬀ ect of ART or HIV immune 
category on the likelihood of children with a positive 
lateral ﬂ ow assay result having deﬁ nite tuberculosis 
rather than no tuberculosis (RR 1·60, 95% CI 0·52–5·01), 
or possible tuberculosis rather than no tuberculosis 
(0·65, 0·25–1·67).
Because culture is insensitive for the diagnosis of 
tuberculosis in children, we did a secondary analysis 
with a broad reference standard, which included both a 
clinical decision to start tuberculosis treatment and 
mycobacterial culture; however, accuracy was not 
improved (area under the ROC curve 0·50, 95% CI 
0·45–0·54; appendix).
ELISA was positive in 21 of 535 (4%) children, including 
two of 89 (2%) with deﬁ nite tuberculosis, ten of 250 (4%) 
with possible tuberculosis, and nine of 196 (5%) with not 
tuberculosis. With culture-conﬁ rmed tuberculosis as the 
reference standard, sensitivity was 2·3% (95% CI 
0·3–7·9) and speciﬁ city 95·7% (93·4–97·4). We recorded 
no diﬀ erence in sensitivity in HIV-positive and HIV-
negative children (p=0·40; table 2), and this result was 
not aﬀ ected by antiretroviral or tuberculosis treatment 
(data not shown).
We noted poor agreement between lipoarabinomannan 
lateral ﬂ ow assay and ELISA for all lateral ﬂ ow assay 
band intensity cutoﬀ  points (ﬁ gure 3); however, we 
recorded a clear trend for increased likelihood of a 
positive ELISA test with increased intensity of bands on 
lateral ﬂ ow assay (p<0·0001). Three of seven children 
(42·9%) with a lateral ﬂ ow assay band intensity stronger 
than 5 had a positive ELISA test.
Discussion
We report the ﬁ rst assessment of the accuracy of urine 
lipoarabinomannan testing with lateral ﬂ ow assay and 
ELISA in children with suspected pulmonary tuberculosis 
(panel). Both assays did poorly against a reference 
standard of culture-conﬁ rmed tuberculosis. Because 
microbiological culture is insensitive for diagnosis of 
tuberculosis in children, we did a secondary analysis for 
the lateral ﬂ ow assay, in which we included a clinical 
decision to start tuberculosis treatment in the reference 
standard; however, test accuracy did not improve. The 
proportion of children with a positive test (either lateral 
ﬂ ow assay or ELISA) was similar in those with deﬁ nite 
tuberculosis, possible tuberculosis, and not tuberculosis. 
By contrast with ﬁ ndings in adults with suspected 
tuberculosis,13,14 accuracy of lateral ﬂ ow assay was not 
substantially improved in children with HIV, and 
advanced immune suppression was not associated with 
increased sensitivity.
The reasons for the poor speciﬁ city of lipo-
arabinomannan testing are unclear. Most of the urine 
samples collected for this study were collected in urine 
bags, which are attached to the perineum. Bags might 
remain on the skin for several hours until the child 
produces urine; therefore, urine might become 
contaminated by bacteria from perineal skin or stool. 
All children 
(n=535)
Deﬁ nite 
tuberculosis 
(n=89)
Possible 
tuberculosis 
(n=250)
Not 
tuberculosis 
(n=196)
p value* p value†
LFA band intensity ≥1 218 (41%) 43 (48%) 95 (38%) 80 (41%) 0·24 0·24
LFA band intensity ≥2 107 (20%) 26 (29%) 42 (17%) 39 (20%) 0·04 0·08
ELISA positive 21 (44%) 2 (2%) 10 (4%) 9 (5%) 0·64 0·34
LFA=lateral ﬂ ow assay.*Comparison between children with deﬁ nite tuberculosis, possible tuberculosis, and not tuberculosis. 
†Comparison between children with deﬁ nite tuberculosis and not tuberculosis.
Table 3: Children with a positive lipoarabinomannan lateral ﬂ ow assay or ELISA, stratiﬁ ed by diagnostic 
categorisation
Figure 2: Receiver operating characteristic curve for lipoarabinomannan lateral ﬂ ow assay with diﬀ erent 
band intensities (stratiﬁ ed by HIV status), with mycobacterial culture as the reference standard
ROC=receiver operating characteristic.
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The polyclonal antibodies used in these assays could 
have cross-reacted with contaminating bacteria, giving 
rise to false-positive results. Unfortunately we did not 
record the method of urine collection or do routine 
bacterial culture, and so cannot establish whether test 
performance was aﬀ ected.
We recorded poor agreement between lateral ﬂ ow assay 
and ELISA, with substantially fewer positive ELISA 
results than lateral ﬂ ow assay. However, we noted that 
stronger band intensity on lateral ﬂ ow assay was 
associated with an increased likelihood of a positive 
ELISA, suggesting that, at least in some cases, the same 
target was detected. This ﬁ nding diﬀ ers from studies 
done in adult patients that showed good correlation 
between lateral ﬂ ow assay (with the ≥2 band intensity 
cutoﬀ ) and ELISA.14,15 Poor agreement is unlikely to be 
attributable to technical reasons because our laboratory 
has previously done studies of adult patients that showed 
good agreement.15 Additionally, lateral ﬂ ow assays were 
repeated with diﬀ erent batches of strips, with similar 
results (data not shown).
Although we hypothesised that lipoarabinomannan 
testing might show improved sensitivity in children 
without HIV compared with adults, this proved not to be 
the case. A possible explanation might be that both HIV-
positive and HIV-negative children enrolled in this study 
did not have disseminated tuberculosis, but rather 
pulmonary tuberculosis, eﬀ ectively conﬁ ned to the 
respiratory system by the child’s immune system. As 
evidence of this, none of the children were severely ill 
and needed intensive care support; none of the children 
recruited at Nolungile Clinic needed hospital admission, 
and no child recruited at Red Cross War Memorial 
Children’s Hospital died in hospital. However, only a 
third of the children with HIV were taking ART, which 
would further enable eﬀ ective containment of 
M tuberculosis. Paucity of ART treatment is worrying, 
highlighting gaps in the present ART programme, 
because all children with HIV should be receiving ART 
according to national policy.
Findings of studies14,15 of HIV-positive adults have 
shown that lipoarabinomannan testing is useful in 
individuals with very advanced disease and severe 
immunosuppression (CD4 count <100 cells per μL); in 
these adults, testing has increased sensitivity and is 
useful for identiﬁ cation of adults at high risk of 
mortality.16 All children enrolled in our study were 
healthy, and all survived at least 6 months of follow-up 
and completion of tuberculosis treatment.
Graham and colleagues17 recently published a proposed 
consensus clinical case deﬁ nition for intrathoracic 
tuberculosis in children. The categorisation used in this 
study was similar for patients with deﬁ nite (or conﬁ rmed) 
tuberculosis. The deﬁ nition used for not tuberculosis 
diﬀ ers from the consensus deﬁ nition in that we were 
able to follow up children, and hence accurately identify 
children who had recovered without treatment for 
tuberculosis. We chose not to further subcategorise 
children into possible and probable categories, but 
grouped these children together in one category to 
simplify the analysis in view of the poor performance of 
the assay in the deﬁ nite and not tuberculosis groups.
Limitations of this study included a small sample size 
of children with HIV, especially those with advanced 
immune suppression, in whom assay sensitivity would 
be expected to be best. Therefore, we cannot make a 
deﬁ nite conclusion for this group of children. However, 
the children enrolled in our study are representative of 
the population of South African children presenting to 
health-care facilities (both ambulatory and hospital) with 
suspected tuberculosis. Second, the poor sensitivity of 
mycobacterial culture in children could have resulted in 
an imperfect reference standard and cause spuriously low 
estimates of speciﬁ city. Although we tested two induced 
sputum samples, microbiological conﬁ rmation of 
tuberculosis was achieved in only a small proportion of all 
children for whom a clinical diagnosis of tuberculosis 
was made; this rate of culture positivity is similar to 
previously reported rates.3 However, the proportion of 
positive tests (lateral ﬂ ow assay or ELISA) was similar in 
children with deﬁ nite tuberculosis and not tuberculosis, 
with high diagnostic certainty. Therefore, the inability to 
conﬁ rm tuberculosis microbiologically is unlikely to have 
led to substantial underestimation of test speciﬁ city. 
Further, urine was frozen for up to 2 years before testing, 
which might have aﬀ ected test performance; however, 
several large studies of adults, which showed promising 
sensitivity for lipoarabinomannan testing, also tested 
urine that had been previously frozen.8,14
Sensitivity and speciﬁ city of urine lipoarabinomannan 
testing with both lateral ﬂ ow assay and ELISA were poor 
Panel: Research in context
Systematic review
We searched PubMed for studies of lipoarabinomannan 
testing published in English from inception up to Jan 14, 
2014, with the following search terms: “tuberculosis” and 
“diagnosis” and (“children” or “child” or “infant”) and 
(“lipoarabinomannan” or “clearview”). We did not identify 
any systematic reviews. We identiﬁ ed four narrative reviews 
and one primary research article12 that included 
lipoarabinomannan testing of 23 adolescents, but did not 
separately report on test accuracy in adolescents.
Interpretation
This is the ﬁ rst study of the accuracy of urine 
lipoarabinomannan testing in children to diagnose 
pulmonary tuberculosis, and showed poor sensitivity and 
speciﬁ city. Test accuracy was poor in children with HIV, 
although this study included only a few HIV-positive 
children with advanced immune suppression in whom test 
accuracy would be expected to be best. Further studies of 
this population of children are needed. 
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in young children with suspected pulmonary tuber-
culosis. Therefore, these tests should not be used to 
diagnose tuberculosis in this patient population.
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